Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 12/11/2019
SIETES contiene 92833 citas

 
 
 1 a 20 de 917 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Mamdani M, Gomes T, Greaves S, Manji S, Juurlink DN, Tadrous M, Kennedy SH, Antoniou T. Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide. JAMA Network Open 2019;2:e1913304. [Ref.ID 103200]
2.Enlace a cita original Cita con resumen
Suchard MA, Schuemie MJ, Krumholz HM, You SC, Chen RJ, Pratt N, Reich CG, Duke J, Madigan D, Hripcsak G, Ryan PB. Comprehensive comparative effectiveness and safety of first-line antihypertensive drug classes: a systematic, multinational, large-scale analysis. Lancet 2019;394:24 de octubre. [Ref.ID 103199]
3.Enlace a cita original Cita con resumen
Bosch J, O'Donnell M, Swaminathan B, Lonn EM, Sharma M, Dagenais G, Diaz R, Khunti K, Lewis BS, Avezum A, Held C, Keltai M, Reid C, Toff WD, Dans A, Leiter LA, Sliwa K, Lee SF, Pogue JM, Hart R, Yusuf S, HOPE-3 Investigators. Effects of blood pressure and lipid lowering on cognition: Results from the HOPE-3 study. Neurology 2019;92:26 de marzo. [Ref.ID 103120]
4.Enlace a cita original Cita con resumen
Anónimo. Towards better patient care: drugs to avoid in 2019. Prescrire Int 2019;39:abril. [Ref.ID 103075]
5.Enlace a cita original Cita con resumen
Anónimo. FDA updates on angiotensin II receptor blocker (ARB) recalls including valsartan, losartan and irbesartan. U.S. Food and Drug Administration 2019:22 de marzo. [Ref.ID 103071]
6.Enlace a cita original Cita con resumen
Byrd JB, Chertow GM, Bhalla V. Hypertension hot potato — Anatomy of the angiotensin-receptor blocker recalls. N Engl J Med 2019;380:25 de abril. [Ref.ID 103055]
8.Enlace a cita original Cita con resumen
Moore TJ, Hanzhe Z, Anderson G, Alexander C. Estimated costs of pivotal trials for novel therapeutic agents approved by the US Food and Drug Administration, 2015-2016. JAMA Intern Med 2018:24 de septiembre. [Ref.ID 102831]
9. Cita con resumen
Reuters Staff. Tainted heart drug from second Chinese firm pulled off EU market. Reuters Health News 2018:20 de agosto. [Ref.ID 102797]
11. Cita con resumen
Anónimo. FDA expands recall of potentially contaminated valsartan. DIA Daily 2018:8 de agosto. [Ref.ID 102753]
13. Cita con resumen
AEMPS. Retirada del mercado de algunos lotes de medicamentos que contienen valsartán. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2018:5 de julio. [Ref.ID 102709]
14.Enlace a cita original Cita con resumen
Patel TK, Patel TB. Mortality among patients due to adverse drug reactions that lead to hospitalization: a meta-analysis. Eur J Clin Pharmacol 2018;74:junio. [Ref.ID 102626]
15. Cita con resumen
Anónimo. Drugs and their names. Drug Ther Bull 2018;56:marzo. [Ref.ID 102507]
16. Cita con resumen
Alharbi FF, Souverein PC, de Groot MCH, Blom MT, de Boer A, Klungel OH, Tan HL. The impact of serum potassium-influencing antihypertensive drugs on the risk of out-of-hospital cardiac arrest: a case–control study. Br J Clin Pharmacol 2017;83:2541-8. [Ref.ID 102115]
17. Cita con resumen
Dimmitt S, Stampfer H, Martin JH. When less is more – Efficacy with less toxicity at the ED50. Br J Clin Pharmacol 2017;83:1365-8. [Ref.ID 101984]
18. Cita con resumen
Rojas-Velandia C, Ruiz-Garzón J, Moscoso-Alcina J-C, Vallejos-Narváez A, Castro-Canoa J, Bustos-Martínez Y, Flórez-Cutiva M, Contreras-Muñoz M, Gómez-Gil JC, Calderón-Ospina C-A. Characterization of adverse drug reactions causing admission to an intensive care unit. Br J Clin Pharmacol 2017;83:1134-40. [Ref.ID 101974]
19. Cita con resumen
Nair NP, Chalmers L, Bereznicki BJ, Curtain C, Peterson GM, Connolly M, Bereznicki LR. Adverse drug reaction-related hospitalizations in elderly Australians: a prospective cross-sectional study in two Tasmanian hospitals. Drug Saf 2017;40:597-606. [Ref.ID 101969]
20. Cita con resumen
Rosich Martí I, Allepuz A, Rodríguez Palomar G, Ortin Font F, Soler Cera M. Impact of an intervention on the prescription of aliskiren after new evidence on safety reported. Pharmacoepidemiol Drug Saf 2017;26:91-6. [Ref.ID 101949]
Seleccionar todas
 
 1 a 20 de 917 siguiente >>